[e-farmacos] Kofi Annan y 7 companhias farmaceuticas sobre ARV

[e-farmacos@usa.healthnet.org]

E-farmacos: Kofi Annan y 7 companhias farmaceuticas sobre ARV
-------------------------------------------------------------------------

[Texto del comunicado de la reunion entre el Secretario General de las
Naciones Unidas y "las 7 grandes" sobre la cuestion de los
antiretrovirales. El texto aparecido en la lista de discusion 'e-.drug'
(gracias) y los reproducimos en e-farmacos para los lectores interesados
en este tema, AF]


Joint communique from Secretary-General and seven leading research-based
pharmaceutical companies on access to HIV/AIDS care and treatment

SG/SM/7982

AIDS/34

4 October 2001

Following is the text of a joint communique issued today in New York by
Secretary-General Kofi Annan and seven pharmaceutical companies:

1. The Secretary-General of the United Nations, Kofi Annan, met today
with the CEOs and senior executives of seven of the world's leading
research-based pharmaceutical companies (Abbott Laboratories,
Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, F.
Hoffmann-La Roche, Merck and Co Inc, and Pfizer) and senior officials of
WHO and UNAIDS, to take stock of progress in expanding access to HIV
treatment and care in developing countries. The meeting followed on an
earlier meeting held in Amsterdam in April of this year.

2. Today's meeting reviewed the extent to which people of least
developed countries, particularly countries of sub-Saharan Africa, are
able to access the HIV care that they need, and ways to increase this
access rapidly.

3. Since the CEOs last met with the Secretary-General, the companies,
acting individually, have taken significant steps to make
HIV/AIDS-related drugs more affordable and available for developing
countries, particularly in sub-Saharan Africa. They have intensified
their partnerships with non-governmental organizations (NGOs), private
employers, local communities and health-care practitioners.

4. The Secretary-General, CEOs and United Nations officials agreed that
prices of medicines and diagnostics are an important component of
efforts to increase access to care, but -- on their own -- reduced
prices are not sufficient to catalyse the scaling up that is needed.
Additional resources are required, together with the political will and
skills to spend them effectively. This means paying careful attention to
the experiences of
individuals and groups who have shown that they are making a difference
to the lives of people at risk of, or affected by, HIV/AIDS. It also
means reporting -- widely -- on what they have achieved, and
synthesizing their
experiences in a way that helps heads of State, governments and
community groups intensify their response to the HIV-related needs of
populations.

5. Participants in the meeting discussed the challenges they face in
detail. They concluded that they will continue, in succeeding months, to
work together on the practical realities of scaling up responses to
HIV/AIDS at community level. They see the need to address HIV/AIDS in a
comprehensive manner with a package of prevention, diagnosis and care.
They recognize that effective care calls for reliable and accessible
diagnosis, and without the potential for care, increasing the impact of
prevention is extremely difficult.

6. With regard to care for people with HIV, the focus will involve
defining the elements of the package concerned with care (including, but
not limited to, anti-retroviral therapy), then identifying and
accrediting those groups who can provide this care; offering support to
these accredited providers so that they make care available to people
who need it and establishing means to subsidize poor people's access to
this care in ways that use scarce resources as efficiently as possible.

7. Participants agreed to join forces with other partners in the fight
against HIV infection and AIDS -- employers (and their workforces),
NGOs, academics, faith-based groups and missions. They will use their 
experience to help governments respond effectively to the needs of all.
They agreed that they would work together to make the Global AIDS and
Health Fund a success. They will communicate and report their results
widely.

8. Summing up, J-P Garnier, on behalf of the companies, said "we will be
working together to put our fingers on the triggers for efficacy". The
Secretary-General endorsed the collective commitment to make a
difference, responding to the enormous challenge of curbing the AIDS
epidemic and the resulting devastation to millions of the world's
poorest people. 



[NOTA: Mensaje sin acentos ni caracteres especiales.]
-
Envíe el correo para la conferencia de `e-farmacos' a:
e-farmacos@usa.healthnet.org
Envíe las peticiones administrativas a:
majordomo@usa.healthnet.org
Para la ayuda adicional, envíe el correo a:
owner-e-farmacos@usa.healthnet.org